Propranolol and lactatemia during hypovolemic shock: A case report;Propranolol et lactatémie durant un choc hypovolémique non septique: À propos d'une observation

Archives de Pediatrie

Volumn 22, Issue 3, 2015, Pages 292-295

  Dobbelaere, D ^a   Leclerc, F ^a   Mention Mulliez, K ^a   Vamecq, J ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CASE REPORT; CYRANO HEMANGIOMA; DEHYDRATION; DISEASE SEVERITY; FEMALE; GLYCOLYSIS; HEMANGIOMA; HUMAN; HYPERLACTATEMIA; HYPOTENSION; HYPOVOLEMIC SHOCK; INFANT; ROTAVIRUS INFECTION; VIRAL GASTROENTERITIS; COMPLICATION; SEVERITY OF ILLNESS INDEX; SHOCK;

ADRENERGIC BETA-ANTAGONISTS; DEHYDRATION; FEMALE; HUMANS; HYPERLACTATEMIA; INFANT; PROPRANOLOL; SEVERITY OF ILLNESS INDEX; SHOCK;

EID: 84923070536     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2014.11.010     Document Type: Article

References (20)

1. Okorie O.N., Dellinger P. Lactate: biomarker and potential therapeutic target. Crit Care Clin 2011, 27:299-326.
2. McCarter F.D., James J.H., Luchette F.A., et al. Adrenergic blockade reduces skeletal muscle glycolysis and Na+, K+-ATPase activity during hemorrhage. J Surg Res 2001, 99:235-244.
3. Gore D.C., Jahoor F., Hibbert J.M., et al. Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Ann Surg 1996, 224:97-102.
4. James J.H., Luchette F.A., McCarter F.D., et al. Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet 1999, 354:505-508.
5. Standage S.W., Wong H.R. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther 2011, 9:71-79.
6. Nduka O.O., Parrillo J.E. The pathophysiology of septic shock. Crit Care Clin 2009, 25:677-702.
7. Bonanno F.G. Physiopathology of shock. J Emerg Trauma Shock 2011, 4:222-232.
8. Bonanno F.G. Shock-a reappraisal: the holistic approach. J Emerg Trauma Shock 2012, 5:167-177.
9. Wynn J.L., Wong H.R. Pathophysiology and treatment of septic shock in neonates. Clin Perinatol 2010, 37:439-479.
10. Rivers E.P., Elkin R., Cannon C.M. Counterpoint: should lactate clearance be substituted for central venous oxygen saturation as goals of early severe sepsis and septic shock therapy? No. Chest 2011, 140:1408-1413.
11. Weil M.H., Afif A.A. Experimental and clinical studies on lactate and pyruvate as indicators of the severity of acute circulatory failure. Circulation 1970, 41:989-1001.
12. Frieden I.J., Drolet B.A. Propranolol for infantile hemangiomas: promise, peril, pathogenesis. Pediatr Dermatol 2009, 26:642-644.
13. Zheng M., Zhu W., Han Q., et al. Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling. Pharmacol Ther 2005, 108:257-268.
14. Wallukat G. The beta-adrenergic receptors. Herz 2002, 27:683-690.
15. Bossuyt J., Despa S., Han F., et al. Isoform specificity of the Na/K-ATPase association and regulation by phospholemman. J Biol Chem 2009, 284:26749-26757.
16. Shattock M.J. Phospholemman: its role in normal cardiac physiology and potential as a druggable target in disease. Curr Opin Pharmacol 2009, 9:160-166.
17. Teriete P., Thai K., Choi J., et al. Effects of PKA phosphorylation on the conformation of the Na,K-ATPase regulatory protein FXYD1. Biochim Biophys Acta 2009, 1788:2462-2470.
18. Boyer P.D. The inhibition of pyruvate kinase by ATP. Biochem Biophys Res Commun 1969, 34:702-706.
19. Fonseca V.A. Effect of β-blockers on glucose and lipid metabolism. Curr Med Res Opin 2010, 26:615-629.
20. Storch C.H., Hoeger P.H. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010, 163:269-274.